This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

The Alzheimer's Drug Discovery Foundation And Charles River Announce Awards For The Cognitive Aging And Alzheimer's Disease Research Program

NEW YORK and WILMINGTON, Mass., April 10, 2012 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and Charles River Laboratories International, Inc. (NYSE: CRL) announced today the recipients of their 2011 partnership award program, Use of Aged Rats as a Relevant Preclinical Model for the Development of Therapeutics for Cognitive Aging and Alzheimer's Disease.  The ADDF and Charles River established the award program to accelerate the discovery of new drugs for cognitive aging and Alzheimer's disease. 

The ADDF/Charles River program awarded $225,000 to two academic research scientists testing novel compounds in aged rats.  The one-year grants were awarded to: John Csernansky, M.D., Northwestern University; and Jerri Rook, Ph.D., Vanderbilt Center for Neuroscience Drug Discovery.  The grant winners have the opportunity to collaborate with Charles River and utilize the Company's aged rat colony as a model for the study of aging and cognitive decline related to Alzheimer's disease. Charles River currently has a unique colony of aged animals which are immediately available in order to aid researchers globally. 

Drs. Csernansky and Rook's projects were selected for funding by an independent panel of experts from the ADDF's Scientific Review Board.  The program received a total of 20 proposals from scientists around the world.

Dr. Csernansky's research program seeks to determine if blocking the effects of stress in the brain will prevent brain cell damage and loss.  Dr. Rook aims to improve brain cell function through a receptor called mGlu5.  This approach significantly slows disease progression and has the potential to be a symptomatic treatment as well as disease-modifying. 

"Aging is the leading risk factor for Alzheimer's disease," said Howard Fillit, M.D., Executive Director, ADDF.  "We are optimistic that these two programs may lead to novel therapeutics for cognitive aging and Alzheimer's disease.  We look forward to continuing our partnership with Charles River again in 2012 and funding more innovative research projects."

"We congratulate Drs. Csernansky and Rook on being chosen for the grant awards.  We are pleased to support their research, which has the potential to advance our knowledge of Alzheimer's disease and therapies for its treatment," said Dr. Davide Molho, Executive Vice President and President, North American Operations.

The ADDF and Charles River will award up to $250,000 in 2012 for the second year of the program.  The deadline for submission is July 10, 2012.  Application details are available on the ADDF website:

About the Alzheimer's Drug Discovery Foundation The mission of the Alzheimer's Drug Discovery Foundation (ADDF) is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. The ADDF has granted more than $51 million to fund over 370 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries.  For more information about the ADDF, please visit

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs